Hecla Mining well-positioned for growth after 2024 results, says H.C. Wainwright
H.C. Wainwright analyst Heiko Ihle reiterates a Buy rating on Hecla Mining (HL) shares after the company reported 2024 financial results. The ...
H.C. Wainwright Keeps Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), ...
HC Wainwright Has Lowered Expectations for Largo (NYSE:LGO) Stock Price
Largo (NYSE:LGO – Get Free Report) had its target price cut by investment analysts at HC Wainwright from $4.20 to $3.70 in a report released on Wednesday,Benzinga reports. The firm currently has a ...
What is HC Wainwright’s Forecast for CRBP FY2029 Earnings?
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
InflaRx launches public offering of shares and warrants
JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has initiated a public offering of its ordinary shares along with pre-funded ...
Why Ocugen (OCGN) Is Advancing Today
Ocugen (OCGN) is climbing 5% after investment bank H.C. Wainwright raised its price target on the shares to $8 from $7.